ACROBiosystems Fuels Global Partnerships at the BIOSeedin Innovation Summit

ACROBiosystems at the BIOSeedin Winter Innovation Summit

On January 11, 2026, the BIOSeedin Winter Innovation Partnering Summit took place in San Francisco ahead of the J.P. Morgan Healthcare Conference. This highly anticipated event was a significant platform for ACROBiosystems, a key strategic partner in the biopharmaceutical industry, which came together with several other companies to discuss collaboration opportunities.

The summit's primary focus was on “global compatibility of innovative assets,” bringing together various stakeholders including pharmaceutical multinationals, investors, and biotechnology firms. With over 500 delegates in attendance, the event fostered deep discussions aimed at facilitating extensive collaboration. Sponsors of the summit included renowned companies such as Lilly, Roche, and Fangda Partners.

Session Highlights

The event revolved around the theme of “capital + collaboration” in global medical innovation. ACROBiosystems showcased its brand message: “Connecting the world, your partner from discovery to clinic,” emphasizing its role in linking resources and encouraging partnerships worldwide. The company aimed to uphold reliable quality and attentive service aligned with its vision.

During the summit, ACROBiosystems established a networking space which allowed participants to engage in more in-depth dialogues with global leaders in pharmaceuticals and biotechnology. The discussions covered crucial topics such as the global expansion of locally developed drugs, licensing opportunities, clinical development, and effective market access strategies to align resources optimally.

Oncology Session

Notably, the oncology session highlighted China’s unique advantages in clinical speed, platform iteration, and portfolio strategy. Panelists forecasted a competitive edge for antibody-drug conjugates (ADCs), T cell engagers (TCEs), and innovations in cell/gene therapy that are expected to emerge from the region soon.

Cardio-Renal-Metabolic Session

In the cardio-renal-metabolic session, experts discussed the reduction of risks associated with clinical trials and acknowledged that small biotech firms are vital drivers of innovation. At the same time, large multinationals leveraged their market advantages to manage cardiovascular strategies.

Autoimmunity Session

The sessions on autoimmunity concentrated on the exciting trends and workings of FIC targets, exploring smarter operational structures, regional stratification, and global coordination to accelerate value creation.

High-profile executives from international pharmaceutical, investment, and biotech companies participated in the panels, including Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, Bayer, GSK, and many more, displaying a strong commitment to fostering innovation.

Startups such as Adagene, Excalipoint Therapeutics, and others presented portfolios featuring a variety of promising developments in antibodies, bispecifics, TCEs, and innovative technologies.

About ACROBiosystems

Founded in 2010 and publicly listed in 2021, ACROBiosystems aims to be a cornerstone of the global biopharmaceutical industry with its innovative products and models. Operating across 16 global cities, the company maintains long-term partnerships with leading pharmaceutical companies and top-tier academic institutes. Its extensive product portfolio includes recombinant proteins, kits, antibodies, and various services, all supported by a stringent quality control system suitable for R&D applications to commercial production.

Through continuous innovation in technology and product development, ACROBiosystems provides valuable solutions to the pharmaceutical industry and empowers its partners in accelerating drug development and improving global health outcomes.